 This is a multiple ascending dosing MAD study of up to 5 treatment regimens cohorts based on using a 33 design up to 30 patients overall. The principal objective is to establish the maximum tolerated dose, safety, tolerability and pharmacokinetic PK profile in blood and urine of this HDAC6 inhibitor in patients with solid tumors and to explore effects on pharmacodynamic markers of target engagement and response to treatment. 